These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31982666)

  • 1. Severe fingolimod rebound syndrome after switching to cladribine treatment.
    Coss-Rovirosa F; Salado-Burbano J; Casallas-Vanegas A; Caire-Herrera LE; Gómez-Figueroa E; Flores-Rivera J
    Mult Scler Relat Disord; 2020 May; 40():101938. PubMed ID: 31982666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO; Torgauten H; Skattebøl L; Høgestøl EA; Sowa P; Myhr KM; Torkildsen Ø; Celius EG
    Mult Scler Relat Disord; 2022 Jun; 62():103812. PubMed ID: 35462167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.
    Sacco R; Emming S; Gobbi C; Zecca C; Monticelli S
    Mult Scler Relat Disord; 2020 May; 40():101927. PubMed ID: 31931457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal.
    Cellerino M; Bonavita S; Ferrero M; Inglese M; Boffa G
    J Neurol Sci; 2020 Nov; 418():117156. PubMed ID: 33010653
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?].
    Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L
    Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe tumefactive rebound of multiple sclerosis following fingolimod cessation.
    Salam S; Mihalova T; Siripurapu R
    BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27261513
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
    Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
    J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod.
    Fragoso YD; Sato HK
    CNS Neurosci Ther; 2016 Jul; 22(7):633-5. PubMed ID: 27140433
    [No Abstract]   [Full Text] [Related]  

  • 12. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
    Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
    Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity after fingolimod cessation: disease reactivation or rebound?
    Frau J; Sormani MP; Signori A; Realmuto S; Baroncini D; Annovazzi P; Signoriello E; Maniscalco GT; La Gioia S; Cordioli C; Frigeni B; Rasia S; Fenu G; Grasso R; Sartori A; Lanzillo R; Stromillo ML; Rossi S; Forci B; Cocco E;
    Eur J Neurol; 2018 Oct; 25(10):1270-1275. PubMed ID: 29851435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothyroidism in multiple sclerosis patient during fingolimod treatment.
    Flores J; Rito Y; Torres G; Jung H; Treviño-Frenk I; Corona T
    J Neurol Sci; 2015 Jan; 348(1-2):272-3. PubMed ID: 25491264
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis.
    Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H
    Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report.
    Navardi S; Sahraian MA; Naser Moghadasi A
    Rev Neurol (Paris); 2020 May; 176(4):289-290. PubMed ID: 31668286
    [No Abstract]   [Full Text] [Related]  

  • 18. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
    Butzkueven H; Moore N; Aydemir A; Sõnajalg J; Bezemer I; Korhonen P; Sabidó M;
    Curr Med Res Opin; 2022 Jul; 38(7):1167-1176. PubMed ID: 35357268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.